Suppr超能文献

[洋地黄、维拉帕米及维拉帕米 - 洋地黄联合治疗急性心肌梗死时血清肌酸磷酸激酶曲线的变化(作者译)]

[Behaviour of serum CPK curves in acute myocardial infarction treated with digitalis, verapamil and combined verapamil-digitalis (author's transl)].

作者信息

Vincenzi M, Allegri P, Cappelletti F, Comacchio G, De Lio U, Morlino T, Ometto R, Zanchetta M, Maiolino P

出版信息

G Ital Cardiol. 1981;11(7):908-17.

PMID:7030855
Abstract

In order to compare the effectiveness of different therapeutic regimens in reducing infarct size serial determinations of CPK activity (at 4 hourly intervals in the first 48 hours from the admission to CCU, at the 72th and at 120th hours) were performed in 100 patients with transmural AMI (53 anterior and 47 inferior) with no obvious evidence of LV failure and basal CPK levels lower than 50 U/L. 20 patients (control group) have been treated with glucose-insulin-potassium (GIK). 20 patients have been treated with GIK plus Verapamil (GIK + V). Verapamil was administered at the dose of 50 mg in continuous drip. 20 patients received GIK plus digoxin at the dose of 0.25 mg b.i.d. (GIK + D). 40 patients received GIK, Verapamil and digoxin at the above doses (GIK + V + D). Different values of CKr and infarct size (IS.) show a statistically significant difference between the various regimens, which is more evident if we consider the whole series. Infarct size was greater in patients treated with digoxin with respect to controls, while it was smaller in patients treated with Verapamil. Combined Verapamil-digoxin therapy is associated to an enzymatic behaviour not different from controls. Authors emphasize that in uncomplicated AMI digoxin causes an increase in infarct size while Verapamil reduces significantly it. Association of Verapamil allows the use of digoxin, if clinically justified, without increase in infarct size.

摘要

为比较不同治疗方案在减小梗死面积方面的有效性,对100例透壁性急性心肌梗死患者(53例前壁梗死和47例下壁梗死)进行了CPK活性的系列测定(从入院至冠心病监护病房的头48小时内每4小时测定一次,在第72小时和第120小时测定),这些患者无明显左室衰竭证据且基础CPK水平低于50 U/L。20例患者(对照组)接受葡萄糖-胰岛素-钾(GIK)治疗。20例患者接受GIK加维拉帕米(GIK + V)治疗。维拉帕米以50 mg持续滴注的剂量给药。20例患者接受GIK加地高辛,剂量为0.25 mg,每日两次(GIK + D)。40例患者接受上述剂量的GIK、维拉帕米和地高辛(GIK + V + D)治疗。不同的CPK值和梗死面积(IS.)在各种治疗方案之间显示出统计学上的显著差异,如果考虑整个系列则更为明显。与对照组相比,接受地高辛治疗的患者梗死面积更大,而接受维拉帕米治疗的患者梗死面积更小。维拉帕米和地高辛联合治疗的酶学表现与对照组无差异。作者强调,在无并发症的急性心肌梗死中,地高辛会导致梗死面积增加,而维拉帕米则可显著减小梗死面积。维拉帕米的联合使用使得在临床合理的情况下可以使用地高辛而不增加梗死面积。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验